Anxiety disorders in dogsâincluding separation anxiety, noise phobias, generalized anxiety, and social fearsâcause significant chronic suffering. Behavioral modification is the cornerstone of treatment, but psychopharmacology (anti-anxiety medications) plays an important adjunctive role in welfare-conscious management of severe or chronic anxiety.
Anxiety in dogs represents a negative affective state involving fear, distress, and anticipatory dread. It is not simply disobedience or misbehavior. Dogs with separation anxiety experience genuine panic during owner absence. Noise-phobic dogs during thunderstorms or fireworks may show extreme physiological stress responses. These states constitute sufferingâand treating them is a welfare imperative, not merely a behavior management issue.
SSRIs (fluoxetine/Reconcile): FDA-approved for canine separation anxiety. Reduces overall anxiety baseline over 4-8 weeks. Used as foundation therapy. TCAs (clomipramine/Clomicalm): Also approved for separation anxiety; similar mechanism. Buspirone: Anxiolytic used for chronic fear states. Situational medications: Trazodone, sileo (dexmedetomidine oromucosal gelâFDA-approved for noise aversion), alprazolam for acute events like fireworks.
Medication alone without behavioral modification rarely resolves anxiety disorders. The welfare-optimal approach combines medication to reduce anxiety baseline, enabling the dog to learn through systematic desensitization and counterconditioning. A veterinary behaviorist consultation is recommended for severe cases.
Acepromazine (ACP) is sometimes misused for noise phobias; it sedates without reducing fearâthe dog is immobile but still terrified. This is a welfare failure. Similarly, suppressing anxiety signs through aversive training creates a dog that appears less anxious but is not. True welfare improvement requires genuine fear reduction.
Part of the Animal Welfare Hub â 2344+ pages of evidence-based animal welfare information.